WHWK on Nasdaq

Whitehawk Therapeutics, Inc.

We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Tvardi Therapeutics, Inc., Ovid Therapeutics Inc. or Immunome Inc., or pick any stock.

  • TickerWHWK on Nasdaq2
  • IndustryPharmaceutical Preparations2
  • HeadquartersCincinnati, United States2
  • Incorporated inDE3
  • Business address2 Headquarters Plaza, East Building, 11Th Floor, Morristown, Nj 079603
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300G3U7TKW1M58L092
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 44590562

See how the biggest companies compare on our leaderboards

We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to approval, launch, and commercialization.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-1601.1%Operating margin5
-288.3%Net margin5
-72.5%Revenue growth, 20255
-15.1%Return on equity5
-$98.0MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue1¢$760.0K
  • Research and development75¢$91.0M
  • Selling, general and admin25¢$29.8M

Out of $7.1M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$7.1M in 2025
0$10.0M$20.0M$30.0M2019: $0$020192020: $14.0M$14.0M20202021: $14.0M$14.0M2021+0%2022: $15.2M$15.2M2022+9%2023: $24.4M$24.4M2023+60%2024: $26.0M$26.0M2024+7%2025: $7.1M$7.1M2025−73%
Operating income6107895-$114.4M in 2025+368% since 2019
-$150.0M-$100.0M-$50.0M02019: -$24.4M-$24.4M20192020: -$2.5M-$2.5M2020−90%2021: -$111.2M-$111.2M2021+4263%2022: -$62.7M-$62.7M2022−44%2023: -$71.9M-$71.9M2023+15%2024: -$67.5M-$67.5M2024−6%2025: -$114.4M-$114.4M2025+70%
Net income6107895-$20.6M in 2025−11% since 2019
-$150.0M-$100.0M-$50.0M02019: -$23.3M-$23.3M20192020: -$3.5M-$3.5M2020−85%2021: -$110.1M-$110.1M2021+3065%2022: -$60.5M-$60.5M2022−45%2023: -$65.8M-$65.8M2023+9%2024: -$63.7M-$63.7M2024−3%2025: -$20.6M-$20.6M2025−68%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Total revenue$7.1M$26.0M
Selling, general and administrative$29.8M$36.7M
Research and development$91.0M$51.0M
Restructuring charges$0$2.6M
Cost of goods sold$760.0K$3.0M
Total operating expenses$121.5M$93.4M
Loss from operations-$114.4M-$67.5M
Gain on sale of business$87.3M$0
Foreign exchange gain (loss)$5.0K-$4.0K
Other income$302.0K$0
Interest income$6.2M$3.9M
Interest expense$0-$154.0K
Total other income (expense), net$93.8M$3.8M
Loss before income tax expense-$20.6M-$63.7M
Income tax expense$0$0
Net loss-$20.6M-$63.7M
Unrealized gain (loss) on investments, net of tax$104.0K-$11.0K
Comprehensive loss-$20.5M-$63.7M
Net loss per share, basic (in dollars per share)-$0.33-$2.36
Net loss per share, diluted (in dollars per share)-$0.33-$2.36
Weighted average number of common shares outstanding, basic (in shares)61.9M shares27.0M shares
Weighted average number of common shares outstanding, diluted (in shares)61.9M shares27.0M shares

Compare Whitehawk Therapeutics, Inc. with another company

Leadership

Who has led Whitehawk Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Stephen J. Hoffman2017–2019
  2. Scott M. Giacobello2023
  3. David James Lennon2023–now

Chair

  1. Neil Desai2023–2024

President

  1. John Pappajohn2008
  2. Joseph H. Gardner2017–2020
  3. Scott M. Giacobello2023

Chief financial officer

  1. Matthew P. Kinley2008
  2. Lance E. Thibault2021
  3. Scott M. Giacobello2021–now

Chief operating officer

  1. Brendan Delaney2021–2022
2010201520202025
Board members and other officers (35)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerLoretta Itri named Oct 11, 202252

Former names

  • Aadi Bioscience, Inc.Aug 27, 2021 to Mar 18, 20253
  • Aerpio Pharmaceuticals, Inc.Mar 17, 2017 to Aug 23, 20213
  • ZETA ACQUISITION CORP IIFeb 1, 2008 to Mar 13, 20173

Timeline

  1. Oct 3, 2023New chief executive David James Lennon becomes CEO14
  2. Apr 4, 2023New chief executive Scott M. Giacobello becomes CEO13
  3. Dec 6, 2017New chief executive Stephen J. Hoffman becomes CEO15
  4. Nov 16, 2007Founded Whitehawk Therapeutics, Inc. is founded2

Filings

309 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 51 major events, 132 insider forms, 37 large holders, 2 private raises, 67 other. The latest 20:

  1. Sep 18, 20264/A EDGAR
  2. Sep 18, 20264/A EDGAR
  3. Sep 18, 20264/A EDGAR
  4. Sep 18, 20264/A EDGAR
  5. Sep 18, 20264/A EDGAR
  6. Sep 15, 20264 EDGAR
  7. Sep 15, 20264 EDGAR
  8. Sep 15, 20264 EDGAR
  9. Sep 15, 20264 EDGAR
  10. Sep 15, 20264 EDGAR
  11. Sep 11, 20264 EDGAR
  12. Sep 11, 20263 EDGAR
  13. Sep 10, 20268-K EDGAR
  14. Aug 14, 2026SCHEDULE 13G/A EDGAR
  15. Aug 14, 2026SCHEDULE 13G/A EDGAR
  16. Aug 6, 202610-Q EDGAR
  17. Aug 6, 20268-K EDGAR
  18. Jul 30, 20264 EDGAR
  19. Jun 15, 20264 EDGAR
  20. Jun 15, 20264 EDGAR

The 309 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

62 open-market trades by officers, directors and large owners since October 2021: 0 buys and 62 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 16, 2026Giacobello Scott M.CHIEF FINANCIAL OFFICERSale141,600$4.13$584.8KForm 4
Apr 15, 2026Giacobello Scott M.CHIEF FINANCIAL OFFICERSale77,000$3.86$297.2KForm 4
Apr 14, 2026BALL BRYANSee remarksSale92,460$3.64$336.6KForm 4
Apr 13, 2026BALL BRYANSee remarksSale26,389$3.46$91.3KForm 4
Apr 10, 2026BALL BRYANSee remarksSale6,596$3.43$22.6KForm 4
Apr 9, 2026Lennon David JamesCHIEF EXECUTIVE OFFICERSale14,500$3.38$49.0KForm 4
Apr 9, 2026BALL BRYANSee remarksSale50,000$3.57$178.5KForm 4
Apr 8, 2026Lennon David JamesCHIEF EXECUTIVE OFFICERSale63,945$3.40$217.4KForm 4
Apr 7, 2026Lennon David JamesCHIEF EXECUTIVE OFFICERSale94,087$3.43$322.7KForm 4
Apr 6, 2026Lennon David JamesCHIEF EXECUTIVE OFFICERSale102,395$3.51$359.4KForm 4
Apr 2, 2026Lennon David JamesCHIEF EXECUTIVE OFFICERSale26,858$3.48$93.5KForm 4
Mar 2, 2026Lennon David JamesCHIEF EXECUTIVE OFFICERSale5,100$3.31$16.9KForm 4
Mar 2, 2026BALL BRYANSee remarksSale1,834$3.31$6.1KForm 4
Mar 2, 2026Giacobello Scott M.CHIEF FINANCIAL OFFICERSale2,594$3.31$8.6KForm 4
Mar 3, 2025BALL BRYANSee remarksSale2,147$2.35$5.0KForm 4
Mar 3, 2025Giacobello Scott M.CHIEF FINANCIAL OFFICERSale2,806$2.35$6.6KForm 4
Mar 3, 2025Lennon David JamesCHIEF EXECUTIVE OFFICERSale5,690$2.35$13.4KForm 4
Oct 3, 2024Lennon David JamesCHIEF EXECUTIVE OFFICERSale9,689$1.94$18.8KForm 4
Sep 3, 2024Desai NeilDirectorSale40,000$1.71$68.4KForm 4
Aug 5, 2024Desai NeilDirectorSale5,652$1.34$7.6KForm 4

All 62 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 4, 2025Raised $100 million in a private offering of equity Form D: 17 investors so far Form D
  2. Sep 26, 2022Raised $72.5 million in a private offering of equity Form D: $72.5 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 78. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Yu Fan4,861,314$22.3M20.6%+2,791,314
Acuta Capital Partners, LLC4,685,912$21.5M15.0%+1,275,510
QVT Financial LP4,615,709$21.1M1.4%No change
Montanova Capital, LLC4,300,000$19.7M0.4%+600,000
Orbimed Advisors LLC3,934,296$18.0M0.3%−231,704
Avoro Capital Advisors LLC2,849,402$13.1M0.1%No change
Siren, L.L.C.2,337,102$10.7M0.2%+255,102
KVP Capital Advisors, LP2,165,997$9.9M7.3%No change
BlackRock, Inc.1,922,828$8.8M0.0%+1,571,443
Vanguard Capital Management LLC1,388,561$6.4M0.0%+72,791
ADAR1 Capital Management, LLC1,341,394$6.1M0.3%+1,212,891
Acorn Capital Advisors, LLC1,139,363$5.2M1.4%No change
Stempoint Capital LP1,021,037$4.7M0.8%−857,701
Geode Capital Management, LLC899,780$4.1M0.0%+442,240
Ally Bridge Group (NY) LLC817,939$3.7M4.8%No change
Woodline Partners LP436,614$2.0M0.0%+155,117
Renaissance Technologies LLC413,822$1.9M0.0%−14,800
State Street Corp386,982$1.8M0.0%+226,600
Millennium Management LLC380,406$1.7M0.0%+70,732
Eversept Partners, LP303,306$1.4M0.1%−3,494
Verdad Advisers, LP301,483$1.4M1.3%+185,999
Two Sigma Investments, LP296,612$1.4M0.0%+23,130
Balyasny Asset Management L.P.288,117$1.3M0.0%−262,324
Northern Trust Corp264,689$1.2M0.0%+157,423
Vanguard Fiduciary Trust Co246,907$1.1M0.0%+32,080

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69